Anti-LY6G6D antibody and its uses

By preparing an anti-LY6G6D antibody with a specific amino acid sequence, the problems of insufficient efficacy and safety of existing drugs have been solved. It achieves high affinity and specific binding, has good endocytosis efficiency, and is suitable for tumor immunotherapy.

CN122749754BActive Publication Date: 2026-11-10CHENGDU CHIPSCREEN NEWWAY BIOSCIENCES CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202611222915.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2026-08-13
Publication Date
2026-11-10
Estimated Expiration
2046-08-13

AI Technical Summary

Technical Problem

Existing antibody drugs targeting LY6G6D have shortcomings in terms of efficacy and safety, and there is an urgent need to develop anti-LY6G6D antibodies with high affinity, high specificity and good biological activity for tumor immunotherapy.

Method used

An anti-LY6G6D antibody or its antigen-binding fragment is provided, comprising specific heavy chain variable region and light chain variable region amino acid sequences, specifically HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, for use in preparing monoclonal, chimeric, or humanized antibodies, and for expression in host cells via an expression vector to form a pharmaceutical composition for treating diseases related to abnormal LY6G6D expression.

Benefits of technology

The prepared antibodies have high affinity and specificity, and can effectively mediate endocytosis, with an endocytosis efficiency of more than 77%, showing good application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122749754B_ABST
    Figure CN122749754B_ABST
Patent Text Reader

Abstract

This invention belongs to the field of biotechnology and provides an anti-LY6G6D antibody and its uses. The antibody comprises: heavy chain variable regions CDR1, CDR2, and CDR3 sequences as shown in SEQ ID NO: 1, 2, and 3; and light chain variable regions CDR1, CDR2, and CDR3 sequences as shown in SEQ ID NO: 4, 5, and 6. The antibody has high specificity and mediates endocytosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to anti-LY6G6D antibodies and their uses, specifically to antibodies that specifically bind to lymphocyte antigen 6 family member G6D (LY6G6D) and methods for preparing them, particularly the use of said antibodies in the treatment of cancer. Background Technology

[0002] Lymphocyte Antigen 6 Family Member G6D (LY6G6D) belongs to the Lymphocyte Antigen-6 (Ly6) gene family, located in the major histocompatibility complex (MHC) class III region on chromosome 6. LY6 superfamily proteins typically contain 70 to 80 amino acids, including 8 to 10 cysteine ​​residues. Most Ly6 proteins are anchored to the cell surface via glycosylphosphatidylinositol (GPI) and participate in signal transduction. Studies have shown that LY6G6D is a protein primarily expressed on the surface of colorectal cancer cells. Given its selective expression in colorectal cancer and its role in the immunosuppressive microenvironment, LY6G6D is considered a potential therapeutic target for cancer. However, existing antibody drugs targeting LY6G6D are still in early development stages, and their efficacy and safety require further validation. Therefore, there is an urgent need in this field to develop novel anti-LY6G6D antibodies with high affinity, high specificity and good biological activity, as well as more effective tumor immunotherapy strategies based on these antibodies. Summary of the Invention

[0003] The technical problem to be solved by the present invention is to provide an antibody or antigen-binding fragment thereof that binds to human lymphocyte antigen 6 family member G6D (Lymphocyte antigen 6 complex locus G6D, LY6G6D).

[0004] In one aspect, the present invention provides an anti-LY6G6D antibody or its antigen-binding fragment, wherein the antibody or its antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising HCDR1, HCDR2, and HCDR3, and the light chain variable region comprising LCDR1, LCDR2, and LCDR3, wherein...

[0005] The amino acid sequence of HCDR1 is shown in SEQ ID NO:1, the amino acid sequence of HCDR2 is shown in SEQ ID NO:2, and the amino acid sequence of HCDR3 is shown in SEQ ID NO:3.

[0006] The amino acid sequence of LCDR1 is shown in SEQ ID NO:4, the amino acid sequence of LCDR2 is shown in SEQ ID NO:5, and the amino acid sequence of LCDR3 is shown in SEQ ID NO:6.

[0007] In some embodiments, the antibody or its antigen-binding fragment is a monoclonal antibody, a single-chain antibody, a chimeric antibody, a humanized antibody, or a human antibody.

[0008] In some embodiments, the antibody or its antigen-binding fragment is a monoclonal antibody.

[0009] In some embodiments, the antibody or its antigen-binding fragment is a chimeric antibody.

[0010] In some embodiments, the antigen-binding fragment is Fab, Fab', F(ab)2, F(ab')2, Fv, or scFv.

[0011] In some embodiments, the antibody or its antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, wherein the amino acid sequence of the heavy chain variable region has at least 90% sequence identity with the sequence shown in SEQ ID NO:7.

[0012] In some embodiments, the antibody or its antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, wherein the amino acid sequence of the light chain variable region has at least 90% sequence identity with the sequence shown in SEQ ID NO:8.

[0013] In some embodiments, the antibody or its antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, wherein the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:7 and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:8.

[0014] In some embodiments, the antibody or its antigen-binding fragment comprises a heavy chain constant region and a light chain constant region.

[0015] In some implementations, the heavy chain constant region is selected from the IgG, IgM, IgA, IgE, or IgD class.

[0016] In some implementations, the heavy chain constant region is human IgG.

[0017] In some implementations, the heavy chain constant region is selected from the heavy chain constant regions of IgG1, IgG2, IgG3 or IgG4 subtypes.

[0018] In some implementations, the light chain constant region is a κ chain or λ chain constant region.

[0019] In some implementations, the light chain constant region is the κ chain constant region.

[0020] In some implementations, the heavy chain constant region is the IgG1 heavy chain constant region or a variant thereof, and the chain constant region is the κ chain constant region or a variant thereof.

[0021] In some embodiments, the amino acid sequence of the heavy chain constant region is shown in SEQ ID NO:9.

[0022] In some embodiments, the amino acid sequence of the light chain constant region is shown in SEQ ID NO:10.

[0023] In another aspect, the present invention provides a biomaterial selected from (a), (b), or (c) below.

[0024] (a) A nucleic acid molecule that encodes the aforementioned antibody or its antigen-binding fragment;

[0025] (b) An expression vector containing the aforementioned nucleic acid molecules;

[0026] (c) A host cell containing the aforementioned nucleic acid molecules and / or the aforementioned expression vectors.

[0027] In some implementations, the nucleic acid molecule may be DNA or RNA, such as cDNA, genomic DNA, recombinant DNA, mRNA, or hnRNA.

[0028] In some embodiments, the expression vector includes bacterial plasmids, bacteriophages, yeast plasmids, plant cell viruses, mammalian cell viruses, retroviruses, or other vectors.

[0029] In some implementations, the host cell can be any prokaryotic or eukaryotic cell, such as bacterial or insect, fungal, plant or animal cells.

[0030] In another aspect, the present invention provides a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof as described in any of the preceding claims or the aforementioned biological material, and a pharmaceutically acceptable carrier.

[0031] In another aspect, the present invention provides a kit containing the antibody or antigen-binding fragment thereof described in any of the foregoing claims or the aforementioned biological material.

[0032] In some implementations, the kit is used to detect LY6G6D in biological samples.

[0033] In another aspect, the present invention provides the use of the antibody or antigen-binding fragment thereof described in any of the foregoing claims, the aforementioned biological material or the aforementioned composition in the preparation of a product for detecting LY6G6D.

[0034] In another aspect, the present invention provides the use of the antibody or antigen-binding fragment thereof described in any of the foregoing claims, the aforementioned biological material or the aforementioned composition in the preparation of a medicament for treating or preventing diseases related to abnormal LY6G6D expression.

[0035] In some implementations, the disease is LY6G6D-related disease.

[0036] In some implementations, the disease is colorectal cancer.

[0037] In another aspect, the present invention provides a method for preparing the aforementioned antibody or antigen-binding fragment thereof, the method comprising culturing the cells described herein under conditions that cause the aforementioned antibody or antigen-binding fragment specifically binding to LY6G6D to be expressed.

[0038] This invention provides an antibody or antigen-binding fragment thereof that specifically binds to LY6G6D. The provided antibody has high affinity and specific binding properties; at the same time, the provided antibody mediates endocytosis with an endocytosis efficiency greater than 77%; the provided antibody has good application prospects. Attached Figure Description

[0039] Figure 1 Plot of antibody Y6 endocytosis rate on HT55 cells Detailed Implementation

[0040] The present invention will be further described below with reference to specific embodiments. It should be understood that the following embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Unless otherwise specified, the techniques used in the embodiments are conventional practices in the art, or experimental methods recommended by the reagent kit and instrument manufacturers. Unless otherwise specified, the reagents and biological materials used in the embodiments are commercially available.

[0041] Certain terms in the invention

[0042] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit this disclosure. Singular expressions include plural expressions unless they have a distinct meaning in the context. As used herein, it should be understood that terms such as “comprising,” “having,” “including,” are intended to indicate the presence of a feature, number, operation, material, or combination thereof. The terminology of the invention is disclosed in the specification and is not intended to exclude the possibility that one or more other features, numbers, operations, materials, or combinations thereof may be present or added. As used herein, “ / ” may be interpreted as “and” or “or,” depending on the context.

[0043] The term "CDR" refers to the complementarity-determining region within the variable sequence of an antibody. For each variable region, there are three CDRs in each variable region of the heavy and light chains, referred to as CDR1, CDR2, and CDR3. The exact boundaries of these CDRs are defined differently depending on the system. The system described by Kabat et al. (Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987) and (1991)) provides not only a well-defined residue numbering system applicable to antibody variable regions but also residue boundaries defining the three CDRs. These CDRs may be referred to as Kabat CDRs. Each complementarity-determining region may contain amino acid residues from what is defined as a "complementarity-determining region" by Kabat.

[0044] The term "antibody" refers to immunoglobulin, a tetrapeptide chain structure composed of two identical heavy chains and two identical light chains linked by interchain disulfide bonds. The amino acid composition and sequence of the constant region of the immunoglobulin heavy chain differ, thus their antigenicity also differs. Based on this, immunoglobulins can be classified into five classes, or different types of immunoglobulins: IgM, IgD, IgG, IgA, and IgE, with their corresponding constant regions of the heavy chain designated α, δ, ε, γ, and μ, respectively. IgG represents the most important class of immunoglobulins, and due to differences in chemical structure and biological function, it can be further divided into four subclasses: IgG1, IgG2, IgG3, and IgG4. The light chains are classified as κ or λ chains based on differences in their constant regions. The subunit structure and three-dimensional conformation of different immunoglobulin classes are well-known to those skilled in the art. The term "chimeric antibody" refers to an antibody containing sequences derived from two different antibodies, typically from different species. For example, a chimeric antibody contains fragments of human and rodent antibodies, typically the human constant region and the mouse variable region. Methods for generating chimeric antibodies include conventional recombinant DNA and gene transfection techniques known to those skilled in the art.

[0045] The term "antigen-binding fragment" refers to an antigen-binding fragment of an antibody and antibody analogues, which typically includes at least a portion of the antigen-binding region or variable region (e.g., one or more CDRs) of the parent antibody. The antibody fragment retains at least some of the binding specificity of the parent antibody. Typically, when activity is expressed on a molar basis, the antibody fragment retains at least 10% of the parent antibody's binding activity. Preferably, the antibody fragment retains at least 20%, 50%, 70%, 80%, 90%, 95%, or 100% or more of the parent antibody's binding affinity to the target. Examples of antigen-binding fragments include, but are not limited to: Fab, Fab', F(ab)2, F(ab')2, Fv fragments, linear antibodies, single-chain antibodies, nanobodies, domain antibodies, and multispecific antibodies.

[0046] The term "specific binding" refers to an antibody that preferentially binds to a specific target protein compared to other proteins, but this specificity does not require absolute binding specificity. Antibody binding depends on the presence of the target protein in the sample; for example, if an antibody specifically binds to the target protein in the sample without producing undesirable results such as false positives, then the antibody is considered "specific" to its intended target. The antibodies or their binding fragments used in this invention will bind to the target protein with an affinity at least two times, preferably at least ten times, more preferably at least 20 times, and most preferably at least 100 times higher than that with non-target proteins.

[0047] The term "humanized antibody," also known as a CDR-grafted antibody, refers to an antibody generated by grafting a mouse CDR sequence into the variable region framework of a human antibody. Humanized antibodies overcome the drawback of chimeric antibodies, which, due to carrying a large amount of mouse protein components, induce a strong immune response. To avoid a decrease in activity along with a decrease in immunogenicity, minimal reverse mutations can be performed on the variable region of the human antibody to maintain its activity.

[0048] The term "chimeric antibody" refers to an antibody formed by fusing the variable region of a murine antibody with the constant region of a human antibody. It can mitigate the immune response induced by murine antibodies. To create a chimeric antibody, a hybridoma that secretes murine-specific monoclonal antibodies is selected. The variable region gene is then cloned from mouse hybridoma cells, followed by the desired human antibody constant region gene. The mouse variable region gene and the human constant region gene are linked to form a chimeric gene, which is then inserted into a human vector. Finally, the chimeric antibody molecule is expressed in a eukaryotic or prokaryotic industrial system. The constant region of the human antibody can be selected from the heavy chain constant region of human IgG1, IgG2, IgG3, or IgG4 or their variants, preferably containing the heavy chain constant region of human IgG1, IgG2, or IgG4. Alternatively, an IgG1 heavy chain constant region that has been mutated to enhance ADCC (antibody-dependent cell-mediated cytotoxicity) can be used.

[0049] The term "human antibody" includes antibodies containing variable and constant regions of human immunoglobulin sequences. Human antibodies as described herein may include amino acid residues not encoded by human immunoglobulin sequences (e.g., mutations introduced through random or site-specific mutagenesis in vitro or through somatic mutations in vivo). However, the term "human antibody" does not include antibodies in which a CDR sequence derived from another mammalian species (such as a mouse) has been grafted onto a human backbone sequence (i.e., "humanized antibody").

[0050] The term "identity" refers to the sequence similarity between two polynucleotide sequences or two polypeptides. When positions in two compared sequences are occupied by the same base or amino acid monomer subunit—for example, if every position in two DNA molecules is occupied by adenine—then the molecules are homologous at that position. The percentage of identity between two sequences is a function of the number of matching or homologous positions shared by the two sequences divided by the number of positions compared, multiplied by 100%. For example, at optimal sequence alignment, if six out of ten positions in two sequences match or are homologous, then the two sequences are 60% homologous. Generally, comparisons are made when the highest percentage of identity is obtained by aligning the two sequences.

[0051] The term "expression vector" or "vector" refers to a delivery system that allows for the operative insertion of polynucleotides or nucleic acids encoding a protein, thereby enabling the expression of that protein. Vectors can be used to transform, transduce, or transfect host cells, allowing the genetic material they carry to be expressed within the host cells.

[0052] The term "host cell" refers to a cell into which a foreign polynucleotide or nucleic acid and / or vector has been introduced. Host cells include "transformers" and "transformed cells," which include the initially transformed cell and its progeny, regardless of the number of passages. Progeny cells may not be identical to parental cells in their nucleic acid content and may contain mutations. This application includes screening or selecting mutant progeny with the same function or biological activity from the initially transformed cells.

[0053] The term “treatment” refers to alleviating a disease or symptom, slowing the onset or development of a disease or symptom, reducing the risk of developing a disease or symptom, or delaying the development of symptoms associated with a disease or symptom, reducing or terminating symptoms associated with a disease or symptom, producing a complete or partial reversal of a disease or symptom, curing a disease or symptom, or a combination of the above.

[0054] The term "prevention" includes the suppression of the occurrence or development of a disease or condition, or symptoms of a particular disease or condition. In some implementations, subjects with a family history of the disease are candidates for preventative programs. Generally, the term "prevention" refers to the administration of a drug before the onset of symptoms or signs, particularly in subjects at risk.

[0055] The term "pharmaceutical composition" herein refers to a composition in which an active substance is formulated together with one or more pharmaceutically acceptable carriers. In some embodiments, the composition is suitable for administration to human or animal subjects. In some embodiments, the active substance is present in a unit dose that is suitable for administration in a treatment regimen and for demonstrating a statistically significant probability of achieving the intended therapeutic effect when used in the relevant population.

[0056] The term “and / or” should be understood to mean any one of the options or any combination of two or more of the options.

[0057] Example 1: Preparation and purification of antibodies

[0058] The nucleotide sequence encoding the extracellular region AA22-104 (uniprotID: O95868) of the human Ly6G6D protein was combined with the his tag and the nucleotide sequence of the mouse Fc fusion protein (synthesized by Suzhou Genewiz), respectively, and inserted into the pcDNA3.4 expression vector at appropriate restriction sites. HEK293 cells were transfected with PEI, and the cell culture supernatant was harvested after expression. The protein containing the his tag was purified by affinity using a Ni column, and the protein containing the mouse Fc was purified by affinity using Protein A to obtain recombinant hLy6G6D-his and hLy6G6D-mFc proteins.

[0059] CHO-K1 Chinese hamster ovary cells (ATCC, CCL-61) were transduced using the pLVX lentiviral vector to express Ly6G6D-IRES from lentiviral particles (Genecopoeia) and cultured in F12K, 10% FBS. In the first passage, selection was performed using genimycin to ensure stable Ly6G6D expression. When cell viability exceeded 80%, single-clone plating was performed at 0.5 cells per well, followed by selection. Single-clone cells with a positivity rate higher than 99% or an MFI at least 1 log shift higher than wild-type were selected and scaled up to obtain the CHOK1-hLY6G6D cell line.

[0060] Several 6-8 week old Balb / c, CD1, KM, FVB, and SJL mice were immunized with recombinant hLy6G6D-mFc protein. For the initial immunization, the antigen was emulsified with complete Freund's adjuvant (CFA) and administered subcutaneously. On days 14 and 28, the antigen was emulsified with incomplete Freund's adjuvant (IFA) and administered intraperitoneally. On day 35, tail blood was collected for ELISA and FACS testing. Mice with the highest ELISA titers and positive FACS results were selected for sprint immunization. Spleen cells were aseptically obtained and single-cell techniques were performed, followed by electrofusion with myeloma cells at a 1:1 ratio. After screening by ELISA and FACS, hybridoma cells corresponding to the supernatant internalized on HT55 cells after binding to recombinant human Ly6G6D protein were selected for 1-2 rounds of cloning. Finally, single-clone cells were selected and cryopreserved. Sequencing was performed, and after recombinant purification and expression, the monoclonal antibody Y6 was obtained.

[0061] The amino acid sequence of the heavy chain variable region of antibody Y6 is shown in SEQ ID NO:7, the amino acid sequence of the light chain variable region is shown in SEQ ID NO:8, the amino acid sequence of the heavy chain is shown in SEQ ID NO:11, the amino acid sequence of the light chain is shown in SEQ ID NO:12, and the CDR sequence of the variable region is shown in SEQ ID NO:1~6 (Kabat numbers) in Table 1.

[0062]

[0063] The control antibody was prepared according to the method described in patent WO2021119505A1 (the amino acid sequences of the heavy and light chains are shown in SEQ ID NO:13 and 14, respectively).

[0064] Example 2: ELISA detection of antibody binding activity

[0065] Recombinant hLY6G6D protein was coated onto 96-well plates (incubated overnight at 4 °C), washed three times with PBST (pH 7.4, containing 0.05% Tween-20), and blocked at 37 °C. The blocking buffer was discarded, and the plates were washed three times. Serially diluted antibodies (Y6 antibody, control antibody) were added, and the plates were incubated at 37 °C for 1 h. After washing three times, HRP-labeled goat anti-human IgG (H+L) (Beyotime #A0201) was added, and the plates were incubated at 37 °C for 1 h. After washing four times, TMB chromogenic buffer was added for color development. After color development was terminated, the OD value was measured at 450 nm using a microplate reader. The results are shown in Table 2.

[0066]

[0067] The results show that antibody Y6 can bind to antigen hLY6G6D, and the binding ability is comparable to that of the control antibody.

[0068] Example 3: FACS detection of antibody binding activity to cell surface hLY6G6D

[0069] HEK293T-hLY6G6D cells stably expressing hLY6G6D were constructed. HEK293T-hLY6G6D cells were cultured, digested, and the cell suspension was collected. Cells were counted, resuspended in pre-chilled PBS, and the cell density was adjusted to 5E6 cells / mL. 20 μL of the cell suspension was added to each well of a 96-well plate. An equal volume of serially diluted 5-fold assay antibody (final concentration range 0–50 μg / mL) was added, mixed, and incubated on ice for 1 h. Cells were washed three times with FACS buffer, and 20 μL of 50-fold diluted PE-labeled anti-human IgG Fc secondary antibody (Biolegend #366904) was added to each well. After incubation on ice for 30 min, cells were washed three times, resuspended in 50 μL of FACS buffer, and PE fluorescence signal was detected by flow cytometry. The results are shown in Table 3.

[0070]

[0071] The results show that the binding ability of antibody Y6 to HEK293T-hLY6G6D is comparable to that of the control antibody.

[0072] Example 4: FACS detection of antibody endocytosis efficiency

[0073] HT55 cells were collected by digestion, washed with pre-chilled PBS, and the cell density was adjusted to 4E6 cells / mL. 50 μL of the cell suspension was added to each well of a 96-well plate (labeled plate A). An equal volume of the test antibody (final concentration 25 μg / mL) was added, mixed, and incubated on ice for 1 h. The cells were washed four times with pre-chilled PBS buffer, and each well was resuspended with 100 μL of complete culture medium. 50 μL of the suspension was transferred to another 96-well plate (labeled plate B). Plate B was placed on ice, and plate A was transferred to 37 °C for 3 h. After incubation, plates A and B were washed once each, and 20 μL of PE-labeled anti-human IgG Fc secondary antibody (2 μg / mL) was added to each well. The cells were incubated on ice for 30 min. After washing three times, the cells were resuspended with 50 μL of FACS buffer, and the PE fluorescence signal was detected by flow cytometry. Endocytosis rate % = (MFI 4 °C - MFI 37 °C) / MFI 4 °C × 100%. The results are shown in Table 4 and Figure 1 As shown.

[0074]

[0075] The results show that the endocytosis rate of antibody Y6 on HT55 cells was 77.40%, while that of the control antibody was 48.20%, indicating that antibody Y6 has a better endocytosis capacity than the control antibody.

Claims

1. An anti-LY6G6D antibody or its antigen-binding fragment, wherein the antibody or its antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising HCDR1, HCDR2, and HCDR3, and the light chain variable region comprising LCDR1, LCDR2, and LCDR3, wherein, The amino acid sequence of HCDR1 is shown in SEQ ID NO:1, the amino acid sequence of HCDR2 is shown in SEQ ID NO:2, and the amino acid sequence of HCDR3 is shown in SEQ ID NO:

3. The amino acid sequence of LCDR1 is shown in SEQ ID NO:4, the amino acid sequence of LCDR2 is shown in SEQ ID NO:5, and the amino acid sequence of LCDR3 is shown in SEQ ID NO:

6.

2. The anti-LY6G6D antibody or its antigen-binding fragment according to claim 1, characterized in that, The antibody is a monoclonal antibody, a single-chain antibody, a chimeric antibody, or a humanized antibody.

3. The anti-LY6G6D antibody or its antigen-binding fragment according to claim 1, characterized in that, The antigen-binding fragments are Fab, Fab', F(ab)2, F(ab')2, Fv, or scFv.

4. The anti-LY6G6D antibody or its antigen-binding fragment according to claim 1, characterized in that, The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:7, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:

8.

5. The anti-LY6G6D antibody or its antigen-binding fragment according to claim 2, characterized in that, It further includes a heavy chain constant region and a light chain constant region, wherein the heavy chain constant region is selected from IgG, IgM, IgA, IgE or IgD, and the light chain constant region is a κ chain or λ chain constant region.

6. A biological material selected from (a), (b) or (c) of the following. (a) A nucleic acid molecule encoding an antibody or an antigen-binding fragment thereof as described in any one of claims 1-5; (b) An expression vector comprising the nucleic acid molecule described in (a); (c) A host cell containing the nucleic acid molecule described in (a) and / or the expression vector described in (b).

7. A reagent comprising the antibody or antigen-binding fragment thereof as described in any one of claims 1-5 or the biological material as described in claim 6.

8. A kit containing the antibody or antigen-binding fragment thereof as described in any one of claims 1-5 or the biological material as described in claim 6, the kit being used to detect LY6G6D in a biological sample.

9. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1-5, the biomaterial according to claim 6, or the reagent according to claim 7 in the preparation of a product for detecting LY6G6D.

Citation Information

Patent Citations

  • Anti-ly6g6d antibodies and methods of use

    WO2021119505A1

  • CD47 antigen-binding molecules

    CN111417653A

  • Anti-LY6G6D antibody or antigen-binding fragment thereof and use thereof

    CN122277734A